EAST HANOVER, N.J., Dec. 4, 2013 /PRNewswire via COMTEX/ -- Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Presentations will provide key scientific evidence for targeted treatments in chronic myeloid leukemia (CML), myelofibrosis (MF) and advanced breast cancer, as well as emerging information on pipeline compounds1,2.
Help employers find you! Check out all the jobs and post your resume.
